In adults with T2DM, GLP-1RA use, primarily dulaglutide, was not associated with lower osteoarthritis risk than DPP4 inhibitor use.
In plain wordsIn adults with diabetes, GLP-1 drugs, mainly dulaglutide, were not linked to lower osteoarthritis risk than DPP4 inhibitors.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- Not applicableOsteoarthritis risk
- Study
n = 2,056,824
- Comparator
- DPP4 inhibitors
- Outcome group
- Bone and joint · Musculoskeletal
Measurements
- Hazard ratio
- 0.93
- GLP-1RAs versus DPP4Is
- 95% CI lower
- 0.83
- hazard ratio
- 95% CI upper
- 1.05
- hazard ratio
Source sentences
Compared to DPP4Is, GLP-1RAs were not associated with a lower risk of osteoarthritis (HR 0.93, 95% CI, 0.83-1.05).
2 context sentences(design, population, supporting numbers)
We conducted a nationwide cohort study applying a target trial emulation framework. From the National Health Insurance Service data of South Korea (2010-2022), eligible patients included adult patients with T2DM initiated GLP-1RAs or DPP4Is.
Among 2,056,824 eligible patients, 9,866 started GLP-1RAs (mean age 45 years; 55% male; 67% dulaglutide) and 2,047,158 started DPP4Is (mean age 56 years; 70% male).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).